A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

TS Fulford; H Van; NA Gherardin; S Zheng; M Ciula; HE Drummer; S Redmond; HX Tan; I Boo; RJ Center; F Li; SL Grimley; BD Wines; THO Nguyen; FL Mordant; P Ellenberg; LC Rowntree; L Kedzierski; AC Cheng; DL Doolan; G Matthews; K Bond; PM Hogarth; Z McQuilten; K Subbarao; K Kedzierska; JA Juno; AK Wheatley; SJ Kent; DA Williamson; DFJ Purcell; DA Anderson; DI Godfrey

Journal article

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

TS Fulford, H Van, NA Gherardin, S Zheng, M Ciula, HE Drummer, S Redmond, HX Tan, I Boo, RJ Center, F Li, SL Grimley, BD Wines, THO Nguyen, FL Mordant, P Ellenberg, LC Rowntree, L Kedzierski, AC Cheng, DL Doolan Show all

Ebiomedicine | Published : 2021

DOI: 10.1016/j.ebiom.2021.103729

Download PDF

Abstract

Background: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure antibody-based protection to SARS-CoV-2, ideally with rapid turnaround and without the need for laboratory-based testing. Methods: We have developed a lateral flow POC test that can measure levels of RBD-ACE2 neutralising antibody (NAb) from whole blood, with a result that can be determined by eye or quantitatively on a small instrument. We compared our lateral flow test with the gold-standard microneutralisation assay, us..

View full abstract

University of Melbourne Researchers

Tom Fulford Author

Samuel Redmond Author

Hyon Xhi Tan Author

Samantha Grimley Author

Related Projects (5)

ANTIGEN PRESENTATION, RECOGNITION AND THE IMMUNE RESPONSE

This program focuses on understanding the development of immunity during infection or inflammatory diseases using a broad array of technique..

AUSTRALIAN PARTNERSHIP FOR PREPAREDNESS RESEARCH ON INFECTIOUS DISEASE EMERGENCIES (APPRISE)

We have assembled national experts in clinical, laboratory and public health research to ensure Australia is equipped for a coordinated, eff..

UNCONVENTIONAL T CELLS IN HEALTH AND DISEASE

The human immune system comprises many different types of cells that can detect foreign molecules. My research will lead the way to understa..

IMPROVED HIV AND INFLUENZA VACCINES

This fellowship is to support Professor Stephen Kent in generating new advances in vaccines to prevent HIV (the cause of AIDS) and Influenza..

APPLYING PATHOGEN GENOMICS TO THE PREVENTION AND CONTROL OF ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is a huge threat to public health, both in Australia and globally. In some instances, having an AMR infection..

Grants

Awarded by State Government of Victoria

Funding Acknowledgements

We are grateful to the volunteers who provided samples for study. The authors would like to thank the Australian Red Cross Lifeblood for the supply of specimens from COVID-19 convalescent plasma donors and `pre-COVID' controls. Australian Governments fund the Australian Red Cross Lifeblood to provide blood, blood products and services to the Australian community. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. This work was supported by grants from the Department of Health and Human Services (DHHS) of the Victorian State Government; the Australian Research Council (ARC; CE140100011, CE140100036) the National Health and Medical Research Council of Australia (NHMRC; 1113293, 2002317 and 1116530), and Medical Research Future Fund (MRFF) Awards (2005544, 2002073, 2002132). THON and AKW were supported by an NHMRC Emerging Leadership Level 1 Investigator Grants (1194036), HV was supported by an NHMRC APPRISE Research Fellowship (1116530), KK was supported by the NHMRC Leadership Investigator Grant (1173871), DLL was supported by a NHMRC Principal Research Fellowship (1137285), KS and DAW are supported by NHMRC Investigator Grants (1177174 and 1174555). KS also received support from the A2 Milk Company and KS, DP and DG received support from the Jack Ma Foundation. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. DIG and SJK were supported by NHMRC Senior Principal Research Fellowships (1117766 and 1136322).